Mariano A Giorgi

Summary

Publications

  1. ncbi Rivaroxaban in atrial fibrillation
    Mariano A Giorgi
    Cardiology Service, Centro de Educación Médica e Investigaciones Clínicas Norberto Quirno, Buenos Aires, Argentina
    Vasc Health Risk Manag 8:525-31. 2012
  2. ncbi QT interval prolongation: preclinical and clinical testing arrhythmogenesis in drugs and regulatory implications
    Mariano A Giorgi
    Department of Cardiology, Instituto FLENI, and Institute of Epidemiological Research, National Academy of Medicine, Buenos Aires, Argentina
    Curr Drug Saf 5:54-7. 2010
  3. ncbi Nonresponders to clopidogrel: pharmacokinetics and interactions involved
    Mariano A Giorgi
    Department of Cardiology and Cardiovascular Surgery, FLENI, Montañeses 2325 1428, Buenos Aires, Argentina
    Expert Opin Pharmacother 11:2391-403. 2010
  4. ncbi Beyond efficacy: pharmacokinetic differences between clopidogrel, prasugrel and ticagrelor
    Mariano A Giorgi
    Department of Cardiology and Cardiovascular Surgery, Instituto FLENI, Montañes, Buenos Aires, Argentina
    Expert Opin Pharmacother 12:1285-95. 2011
  5. ncbi Changing anticoagulant paradigms for atrial fibrillation: dabigatran, apixaban and rivaroxaban
    Mariano A Giorgi
    Department of Cardiology and Cardiovascular Surgery, FLENI, Montañeses 2325 1428, Buenos Aires, Argentina
    Expert Opin Pharmacother 12:567-77. 2011
  6. ncbi Pharmacogenomics and adverse drug reactions: the case of statins
    Mariano A Giorgi
    Department of Cardiology and Cardiovascular Surgery, Montañeses 2325 1428, FLENI, Buenos Aires, Argentina
    Expert Opin Pharmacother 12:1499-509. 2011

Collaborators

Detail Information

Publications6

  1. ncbi Rivaroxaban in atrial fibrillation
    Mariano A Giorgi
    Cardiology Service, Centro de Educación Médica e Investigaciones Clínicas Norberto Quirno, Buenos Aires, Argentina
    Vasc Health Risk Manag 8:525-31. 2012
    ..Rivaroxaban is an attractive alternative, but the true picture of this novel compound in atrial fibrillation will only become available with more widespread use...
  2. ncbi QT interval prolongation: preclinical and clinical testing arrhythmogenesis in drugs and regulatory implications
    Mariano A Giorgi
    Department of Cardiology, Instituto FLENI, and Institute of Epidemiological Research, National Academy of Medicine, Buenos Aires, Argentina
    Curr Drug Saf 5:54-7. 2010
    ....
  3. ncbi Nonresponders to clopidogrel: pharmacokinetics and interactions involved
    Mariano A Giorgi
    Department of Cardiology and Cardiovascular Surgery, FLENI, Montañeses 2325 1428, Buenos Aires, Argentina
    Expert Opin Pharmacother 11:2391-403. 2010
    ..g., between proton pump inhibitors (PPIs) and clopidogrel) are both associated with decreased clopidogrel efficacy. Despite all PPIs being potent inhibitors of CYP2C19, evidence about their clinical impact is controversial...
  4. ncbi Beyond efficacy: pharmacokinetic differences between clopidogrel, prasugrel and ticagrelor
    Mariano A Giorgi
    Department of Cardiology and Cardiovascular Surgery, Instituto FLENI, Montañes, Buenos Aires, Argentina
    Expert Opin Pharmacother 12:1285-95. 2011
    ..However, the pharmacokinetic advantages of both prasugrel and ticagrelor allow clinicians to center patient management by selecting the best drug for the appropriate subject...
  5. ncbi Changing anticoagulant paradigms for atrial fibrillation: dabigatran, apixaban and rivaroxaban
    Mariano A Giorgi
    Department of Cardiology and Cardiovascular Surgery, FLENI, Montañeses 2325 1428, Buenos Aires, Argentina
    Expert Opin Pharmacother 12:567-77. 2011
    ..Therefore, it is important to know the characteristics of these drugs as a potential alternative to VKAs...
  6. ncbi Pharmacogenomics and adverse drug reactions: the case of statins
    Mariano A Giorgi
    Department of Cardiology and Cardiovascular Surgery, Montañeses 2325 1428, FLENI, Buenos Aires, Argentina
    Expert Opin Pharmacother 12:1499-509. 2011
    ..EXPERT OPINION: Despite there being a statin-gene association for myopathy, in the case of some statins the usefulness of this information still needs to be proven...